RICCI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 94
AS - Asia 76
SA - Sud America 24
EU - Europa 21
AF - Africa 1
OC - Oceania 1
Totale 217
Nazione #
US - Stati Uniti d'America 92
SG - Singapore 59
BR - Brasile 23
CN - Cina 8
IT - Italia 8
FI - Finlandia 4
IE - Irlanda 4
DE - Germania 3
HK - Hong Kong 2
TR - Turchia 2
AU - Australia 1
BD - Bangladesh 1
CA - Canada 1
GB - Regno Unito 1
IN - India 1
IQ - Iraq 1
MA - Marocco 1
MX - Messico 1
NP - Nepal 1
PK - Pakistan 1
PL - Polonia 1
VE - Venezuela 1
Totale 217
Città #
Santa Clara 58
Singapore 49
Chicago 6
Civitanova Marche 4
Dublin 4
Turku 4
Boardman 3
Hefei 3
Bastiglia 2
Curitiba 2
Hong Kong 2
Munich 2
Porto Alegre 2
São Paulo 2
Vitória 2
Ashburn 1
Beijing 1
Boston 1
Cambridge 1
Caracas 1
Carapicuíba 1
Caratinga 1
Casablanca 1
Catania 1
Citrus Heights 1
Cleveland 1
Covington 1
Dhaka 1
Erbil 1
Gonzales 1
Gravataí 1
Guarulhos 1
Kahramanmaraş 1
Karachi 1
Karlsruhe 1
Konya 1
Laguna 1
Lawrence 1
Manaus 1
Montreal 1
Moreilândia 1
New York 1
Nova Serrana 1
Petrópolis 1
Piraí do Sul 1
Ribeirão Preto 1
Salvador 1
Slough 1
Suzano 1
Sydney 1
São Francisco do Sul 1
Thāne 1
Ubá 1
Warsaw 1
Zapopan 1
Totale 185
Nome #
Discovering cosmic rays with OCRA: outreach activities for students and teachers 38
Further delineation and long-term evolution of electroclinical phenotype in Mowat Wilson Syndrome. A longitudinal study in 40 individuals 31
The online laboratories for OCRA - Outreach Cosmic Ray Activities INFN project 28
Weight gain: A possible side effect of all antiretrovirals 18
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 17
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 14
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir 13
Factors associated with weight gain in people treated with dolutegravir 13
Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine: Data from the SCOLTA project 7
96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: A multicentre Italian experience 7
Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals 6
The effect of switching from tenofovir disoproxil fumarate (Tdf) to tenofovir alafenamide (taf) on liver enzymes, glucose, and lipid profile 5
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: The SALIR-E Study 5
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 5
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: The HIVand Hypertension Study 5
Effectiveness of first-generation HCV protease inhibitors: Does HIV coinfection still play a role? 5
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? 5
Low frequency of skin reactions in a cohort of patients on raltegravir 5
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance 4
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project) 4
Decreasing cardiovascular risk in HIV infection between 2005 and 2011 3
Totale 238
Categoria #
all - tutte 1.551
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.551


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 0 0 0 0 0 0 0 1 0 1
2022/20235 1 0 0 0 0 1 0 1 2 0 0 0
2023/202412 0 0 1 1 0 0 0 0 0 2 6 2
2024/2025219 1 9 5 6 44 28 6 5 27 31 26 31
Totale 238